Trial Profile

A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idronoxil (Primary)
Indications COVID 2019 infections; Multiple organ failure; SARS-CoV-2 acute respiratory disease; SARS-CoV-2 sepsis; Septic shock
Focus Adverse reactions
Acronyms NOXCOVID; NOXCOVID-1
Sponsors Noxopharm

Most Recent Events

25 Aug 2021 According to a Noxopharm media release, based on initial positive results from this trial, company has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
25 Aug 2021 Results presented in a Noxopharm Media Release.
24 Aug 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com